spacer
spacer

PDBsum entry 3fvh

Go to PDB code: 
protein ligands links
Cell cycle, peptide binding protein PDB id
3fvh

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
233 a.a. *
Ligands
ACE-LEU-HIS-SER-
TPO-ALA-NH2
Waters ×262
* Residue conservation analysis
PDB id:
3fvh
Name: Cell cycle, peptide binding protein
Title: Polo-like kinase 1 polo box domain in complex with ac-lhspta-nh2 peptide
Structure: Serine/threonine-protein kinase plk1. Chain: a. Synonym: polo-like kinase 1, plk-1, serine/threonine-protein kinase 13, stpk13. Engineered: yes. Acetyl-leu-his-ser-phosphothr-ala-nh2 peptide. Chain: b. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: plk, plk1. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Other_details: the peptide was chemically synthesized
Resolution:
1.58Å     R-factor:   0.194     R-free:   0.227
Authors: D.C.Lim,M.B.Yaffe
Key ref:
S.M.Yun et al. (2009). Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Biol, 16, 876-882. PubMed id: 19597481 DOI: 10.1038/nsmb.1628
Date:
15-Jan-09     Release date:   04-Aug-09    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P53350  (PLK1_HUMAN) -  Serine/threonine-protein kinase PLK1 from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
603 a.a.
233 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: E.C.2.7.11.21  - polo kinase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction:
1. L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
2. L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
L-seryl-[protein]
+ ATP
= O-phospho-L-seryl-[protein]
+ ADP
+ H(+)
L-threonyl-[protein]
+ ATP
= O-phospho-L-threonyl-[protein]
+ ADP
+ H(+)
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
DOI no: 10.1038/nsmb.1628 Nat Struct Biol 16:876-882 (2009)
PubMed id: 19597481  
 
 
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.
S.M.Yun, T.Moulaei, D.Lim, J.K.Bang, J.E.Park, S.R.Shenoy, F.Liu, Y.H.Kang, C.Liao, N.K.Soung, S.Lee, D.Y.Yoon, Y.Lim, D.H.Lee, A.Otaka, E.Appella, J.B.McMahon, M.C.Nicklaus, T.R.Burke, M.B.Yaffe, A.Wlodawer, K.S.Lee.
 
  ABSTRACT  
 
Polo-like kinase-1 (Plk1) has a pivotal role in cell proliferation and is considered a potential target for anticancer therapy. The noncatalytic polo-box domain (PBD) of Plk1 forms a phosphoepitope binding module for protein-protein interaction. Here, we report the identification of minimal phosphopeptides that specifically interact with the PBD of human PLK1, but not those of the closely related PLK2 and PLK3. Comparative binding studies and analyses of crystal structures of the PLK1 PBD in complex with the minimal phosphopeptides revealed that the C-terminal SpT dipeptide functions as a high-affinity anchor, whereas the N-terminal residues are crucial for providing specificity and affinity to the interaction. Inhibition of the PLK1 PBD by phosphothreonine mimetic peptides was sufficient to induce mitotic arrest and apoptotic cell death. The mode of interaction between the minimal peptide and PBD may provide a template for designing therapeutic agents that target PLK1.
 
  Selected figure(s)  
 
Figure 1.
(a–c) Various lengths of N-terminal Cys-(CH[2])[6]–fused Thr78 peptides were cross-linked to beads (a) and then tested for their ability to precipitate PLK1 from mitotic HeLa lysates. The phosphorylated Thr78 residue ('T' in red) and the invariable Ser77 residue ('S' in blue) crucial for PBD binding are indicated in a (above right). Immunoblots with antibody to PLK1 show levels of PLK1 coprecipitated with the indicated peptides. A shortened form of the synthetic peptide optimized for PLK1 PBD binding (MQSpTPL)^13 was included for comparison. Numbers indicate efficiency of PLK1 precipitation by each peptide relative to the PLK1 signal in the input. (d) A 6-mer Thr78 peptide (LHSpTAI) analogous to the synthetic optimal peptide (MQSpTPL) was tested for PLK1 binding as in a–c.
Figure 3.
(a) Superposition of phosphopeptide binding pockets of PBD^PL, PBD^PP, PBD^S+G and PBD^S. Gray, PBD; green, PLHSpT; yellow, PLHSpT-associated glycerol molecule; cyan, PPHSpT; magenta, glycerol molecule (two half-occupancy conformations at Ser–1 position) of PBD^S+G; black, two sulfate anions of PBD^S+G and PBD^S (red, oxygen atoms). Differences in exact positions of sulfate and phosphate groups could result from the fact that sulfate is a free anion, whereas phosphate is covalently linked to the phosphopeptide. (b) PBD residues involved in binding of PLHSpT are labeled and shown in cyan. All water molecules that form an interface between the phosphopeptide and PBD are drawn in red mesh. (c) Superposition of PLHSpT (green), PPHSpT (cyan), MQSpTPL (magenta) and PMQSpTPL (gray). (d,e) Mixture of HeLa lysates expressing kinase-inactive Flag-PLK1(K82M), Flag-PLK2(K108M) or Flag-PLK3(K52R) was subjected to pull-down assays as in Figure 2a, with the indicated 5-mer wild-type (PLHSpT) and mutants cross-linked to beads. The nonphosphorylated Thr78 peptide PLHST was used as a control. Numbers above the blot indicate relative efficiency of PLK2 precipitation; numbers below denote relative efficiency of PLK1 precipitation. (f) Nature of interactions between SpT-containing peptides and PLK1 PBD. Alignment of minimal p-T78 peptides (PLHST and LHSTA) and synthetic optimal peptides (PMQSTPL and MQSTPL) are shown. See text for details.
 
  The above figures are reprinted by permission from Macmillan Publishers Ltd: Nat Struct Biol (2009, 16, 876-882) copyright 2009.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
20502673 A.Stein, and P.Aloy (2010).
Novel peptide-mediated interactions derived from high-resolution 3-dimensional structures.
  PLoS Comput Biol, 6, e1000789.  
  20625469 C.Liao, J.E.Park, J.K.Bang, M.C.Nicklaus, and K.S.Lee (2010).
Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1.
  ACS Med Chem Lett, 1, 110-114.  
  20711360 D.J.Huggins, G.J.McKenzie, D.D.Robinson, A.J.Narváez, B.Hardwick, M.Roberts-Thomson, A.R.Venkitaraman, G.H.Grant, and M.C.Payne (2010).
Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation.
  PLoS Comput Biol, 6, 0.  
20148280 J.E.Park, N.K.Soung, Y.Johmura, Y.H.Kang, C.Liao, K.H.Lee, C.H.Park, M.C.Nicklaus, and K.S.Lee (2010).
Polo-box domain: a versatile mediator of polo-like kinase function.
  Cell Mol Life Sci, 67, 1957-1970.  
20671765 K.Strebhardt (2010).
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
  Nat Rev Drug Discov, 9, 643-660.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.

 

spacer

spacer